SCPH
vs
S&P 500
SCPH
S&P 500
Over the past 12 months, SCPH has significantly outperformed S&P 500, delivering a return of +66% compared to the S&P 500's +14% growth.
Stocks Performance
SCPH vs S&P 500
Performance Gap
SCPH vs S&P 500
Performance By Year
SCPH vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
scPharmaceuticals Inc
Glance View
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2017-11-17. The firm is focused on exploring, developing and commercializing products that expand and advance the outpatient care of acute conditions, including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for treatment of congestion in patients with heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization. Its area of focus is congestion in heart failure and outpatient parenteral antimicrobial therapy (OPAT). Its pipeline programs include FUROSCIX, scCeftriaxone and scCarbapenem. Its FUROSCIX On-Body Infusor is a drug-device combination product consisting of FUROSCIX. The firm's wholly owned subsidiary is scPharmaceuticals Securities Corporation.
